103 related articles for article (PubMed ID: 32482026)
1. [Genetic variations in apoptosis genes are associated with acute adverse events in postoperative rectal cancer patients receiving concurrent chemoradiotherapy].
Yin LL; Yang J; Feng YR; Huang Y; Feng T; Chen JN; Chen HX; Lin DX; Li YX; Jin J; Tan W
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):376-382. PubMed ID: 32482026
[No Abstract] [Full Text] [Related]
2. [Associations of genetic variations in pyroptosis related genes with acute adverse events in postoperative rectal cancer patients receiving concurrent chemoradiotherapy].
Chen HX; Ren NX; Yang J; Chen JN; Lu QX; Feng YR; Huang Y; Yin LL; Lin DX; Li YX; Jin J; Tan W
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):146-152. PubMed ID: 36781235
[No Abstract] [Full Text] [Related]
3. [Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy].
Qiao Y; Ren H; Huang Y; DU ZL; Yu DK; Jin J; Li YX; Lin DX; Tan W
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):268-72. PubMed ID: 23985254
[TBL] [Abstract][Full Text] [Related]
4. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
[TBL] [Abstract][Full Text] [Related]
5. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
6. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
[TBL] [Abstract][Full Text] [Related]
8. [Genetic variations in MLH3 and MSH2 genes are associated with the sensitivity and prognosis in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy].
Yang J; Wang X; Zou SM; Li HM; Xiao Q; Feng YR; Huang Y; Feng T; Chen JN; Lin DX; Li YX; Jin J; Tan W
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):433-440. PubMed ID: 29936769
[No Abstract] [Full Text] [Related]
9. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Garcia-Aguilar J; Chow OS; Smith DD; Marcet JE; Cataldo PA; Varma MG; Kumar AS; Oommen S; Coutsoftides T; Hunt SR; Stamos MJ; Ternent CA; Herzig DO; Fichera A; Polite BN; Dietz DW; Patil S; Avila K;
Lancet Oncol; 2015 Aug; 16(8):957-66. PubMed ID: 26187751
[TBL] [Abstract][Full Text] [Related]
10. Associations of Genetic Variations in Mismatch Repair Genes MSH3 and PMS1 with Acute Adverse Events and Survival in Patients with Rectal Cancer Receiving Postoperative Chemoradiotherapy.
Yang J; Huang Y; Feng Y; Li H; Feng T; Chen J; Yin L; Wang W; Wang S; Liu Y; Song Y; Li Y; Jin J; Tan W; Lin D
Cancer Res Treat; 2019 Jul; 51(3):1198-1206. PubMed ID: 30590005
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
13. [Neoadjuvant chemoradiotherapy with capecitabine and oxaliplatin for the treatment of locally advanced lower rectal cancer].
Murata K; Okamura S; Okubo H; Owada Y; Nishigaki T; Wada Y; Kato R; Makino S; Takeoka T; Okada K; Fukuchi N; Ebisui C; Kinuta M
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2020-2. PubMed ID: 24393999
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
Gao YH; An X; Sun WJ; Cai J; Cai MY; Kong LH; Lin JZ; Liu GC; Tang JH; Wu XJ; Chen G; Pan ZZ; Ding PR
J Surg Oncol; 2014 Apr; 109(5):478-82. PubMed ID: 24288203
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
[TBL] [Abstract][Full Text] [Related]
19. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
[TBL] [Abstract][Full Text] [Related]
20. Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer.
Yang Y; Liu Q; Jia B; Du X; Dai G; Liu H; Chen J; Zeng M; Wen K; Zhu Y; Wang Y; Feng L
Technol Cancer Res Treat; 2019 Jan; 18():1533033818824367. PubMed ID: 30803368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]